Alimera Sciences, Inc. (ALIM) Posts Smaller Q2 Loss

Alimera Sciences, Inc. (NASDAQ: ALIM) reported Q2 EPS of ($0.15), $0.08 better than the analyst estimate of ($0.23). Revenue for the quarter came in at $2.2 million versus the consensus estimate of $2.7 million.

"We achieved an important milestone during the second quarter of 2014 as more commercial patients have now been injected with ILUVIEN than were treated in our clinical trials. Further, we experienced a 25% increase in ILUVIEN injections in the United Kingdom during the second quarter of 2014 compared to the prior quarter. Our second quarter 2014 revenue from the United Kingdom was similar to the first quarter revenue as several hospitals in the United Kingdom stocked their pharmacies following the implementation of the NICE guidance for the reimbursement of ILUVIEN in the first quarter 2014," said Dan Myers, president and chief executive officer of Alimera Sciences. "As our operations continue to expand, we expect to experience fluctuations in order patterns but we believe the underlying organic growth rate of ILUVIEN injections in the United Kingdom is a strong sign of the demand we are seeing. We expect usage to continue to increase as the United Kingdom market becomes more familiar with the available treatments for diabetic macular edema."

For earnings history and earnings-related data on Alimera Sciences, Inc. (ALIM) click here.

You May Also Be Interested In

• JPMorgan Upgrades Aviva Plc (AV/:LN) (AIVAF) to Overweight
• North American Construction (NOA) Tops Q2 EPS by 9c; Offers Guidance
• Park Dental Partners, Inc. (PARK) Tops Q2 EPS by 28c